Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.38 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL698941 | 0.90 | RBP4 (0.50) | RBP4SMOALDH1A1SIGMAR1MGLL | |
| SCHEMBL5130274 | 0.84 | RBP4 (0.51) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL970704 | 0.83 | RBP4 (0.50) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL16862022 | 0.81 | SMO (0.54) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL17761042 | 0.81 | RBP4 (0.49) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL23213437 | 0.80 | HPGD (0.49) | RBP4SMOALDH1A1HPGDHTR2C | |
| SCHEMBL28740942 | 0.80 | RBP4 (0.48) | RBP4SMOALDH1A1MGLLABL1 | |
| SCHEMBL693819 | 0.79 | MGLL (0.50) | RBP4SMOMGLL | |
| SCHEMBL2721136 | 0.79 | RBP4 (0.51) | RBP4SMOALDH1A1MGLL | |
| Hydrochloric Acid SCHEMBL14813360 | 0.78 | MGLL (0.49) | RBP4SMOMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087067-B1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-24 | — | — | EP | disclosed |
| CN-107714702-A | A kind of Ivabradine and milrinone composition and its application in pharmacy | 泰州中国医药城中医药研究院 | 2018-02-23 | — | — | CN | disclosed |
| CN-107648224-A | A kind for the treatment of and prevention heart failure drugs and its application in pharmacy | 泰州中国医药城中医药研究院 | 2018-02-02 | — | — | CN | disclosed |
| CN-107550915-A | A kind of Ivabradine and rolipram composition and its application in pharmacy | 泰州中国医药城中医药研究院 | 2018-01-09 | — | — | CN | disclosed |
| CN-106727487-A | Application of the Atisine chloride Atractydin in pharmacy | 泰州中国医药城中医药研究院 | 2017-05-31 | — | — | CN | disclosed |
| US-9624170-B2 | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-03 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124082-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| US-7494992-B2 | Antiparasitic terpene alkaloids | PFIZER INC. (US) | 2009-02-24 | — | — | US | disclosed |
| CN-101361740-A | Pharmacy use of 2,5- bis (hydroxymethyl)-3,6-dimethyl pyrazine and derivates thereof | UNIV NANJING TRAD CHINESE MED (CN) | 2009-02-11 | — | — | CN | disclosed |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | PFIZER PRODUCTS INC | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318864-A1 | 4-(PIPERRAZIN-1-YL)-PYRROLIDIN-2-ONE COMPOUNDS AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, PNLIP, LYPLAL1 | RBP4 4209/4885SMO 3266/4885ALDH1A1 470/4885 |
| US-20070185101-A1 | Antiparasitic terpene alkaloids | CYP51A1, DHPS, CYP8B1 | RBP4 4788/4885SMO 3886/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.